TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05296590

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width (MDW) , observation
Description: Observation of MDW performance blinded to treating clinical teams

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width (MDW) , observation
Description: Observation of MDW performance blinded to treating clinical teams

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width (MDW) , observation
Description: Observation of MDW performance blinded to treating clinical teams

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width (MDW) , observation
Description: Observation of MDW performance blinded to treating clinical teams
Study: NCT05260918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Float-REST
Description: Participants will utilize sensory deprivation tanks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nappod
Description: Participants will utilize nappod.
Study: NCT04590833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised walking on a treadmill
Description: Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised stretching exercise
Description: Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
Study: NCT05982262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naturopathic-pharmacological consultation
Description: The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.
Study: NCT04107389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Art Psychotherapy, Art Therapy
Description: Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait List
Description: Wait list control group. Participants randomised to Wait List group or Intervention group.
Study: NCT04608539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose
Description: Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Single-dose infusion (placebo), postoperative day 1
Study: NCT04865926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular and Neck Proprioceptive Neuromuscular Facilitation exercises
Description: The researcher will perform a total of 12 sessions of scapular and neck pnf exercises for 4 weeks. The participants will apply PNF exercises using rhythmic initiation, rhythmic stabilization and cobination techniques of isotonics. Patterns of anterior elevation, posterior depression, anterior depression, posterior elevation will be used in scapular exercises. Upper cervical flexion, lower cervical flexion, rotation and lateral flexion patterns will be used in neck pnf exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie and Kendall exercises
Description: Kendall and Mckenzie exercises will be given to the participants as a home workout. The self-stretch exercise methods are as followed: Placing both hands on the shoulders and pushing out the chest, placing one hand over the shoulder and grasp the elbow of the turned hand, with the other hand over the head and slowly pull it inward, throwback the head until it has reached the fully stretched point, look straight ahead and slowly turn the head horizontally until the maximum value is reached, throwback the head, and turn it until it has reached the fully stretched point, lower the head turn it until it has reached the maximal point. Stretching pectoralis muscle, strengthening shoulder retraction, strengthening the deep cervical flexors, strengthening the deep cervical flexors.
Study: NCT05719480

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
Study: NCT05902650

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: imaging
Study: NCT06271278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: Emotional Freedom Technique (EFT) is a powerful and effective practice that enables individuals to release negative emotions and achieve mental and physical relaxation. EFT is a form of counselling based on acupuncture points, which are areas of low electrical and energy flow in the body. Stimulating these points causes the brain to secrete dopamine. EFT involves stimulating specific points on the body where energy flow is low. This is done by gently tapping on these areas with the fingers, which releases dopamine. The process is painless and can be performed by the individual themselves.
Study: NCT06551246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: According to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: According to randomization.
Study: NCT05902650

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: imaging
Study: NCT06551246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: According to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: According to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: According to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: According to randomization.
Study: NCT05719480

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
Study: NCT05000346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug, inhalation
Description: Solution administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug, inhalation
Description: Solution administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug, inhalation
Description: Solution administered by inhalation
Study: NCT06107010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Atalante exoskeleton
Description: Six weeks of exoskeleton sessions replacing conventional therapy sessions three times a week
Study: NCT05205408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: Administered by intratumoral injection as single agent.
Study: NCT04702009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy
Description: Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy
Description: Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy-assisted Interventional Therapy
Description: Bronchoscopy-assisted interventional therapy (1 time before chemotherapy or 2 times before chemotherapy and before the third cycle of treatment)
Study: NCT05350462

Intervention type: BEHAVIORAL
Intervention: Community pilot L-PZQ distribution - intervention is NOT part of this observational study
Description: Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.

Intervention type: BEHAVIORAL
Intervention: Community pilot L-PZQ distribution - intervention is NOT part of this observational study
Description: Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.

Intervention type: BEHAVIORAL
Intervention: Community pilot L-PZQ distribution - intervention is NOT part of this observational study
Description: Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.

Intervention type: BEHAVIORAL
Intervention: Community pilot L-PZQ distribution - intervention is NOT part of this observational study
Description: Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.

Intervention type: BEHAVIORAL
Intervention: Community pilot L-PZQ distribution - intervention is NOT part of this observational study
Description: Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.

Intervention type: BEHAVIORAL
Intervention: Community pilot L-PZQ distribution - intervention is NOT part of this observational study
Description: Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
Study: NCT06770400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature Optimized for Sleep
Description: Using the cloud-controlled thermostat, we will prescribed bedroom temperature based on the observed relationship between the individual's sleep quality and the temperature of their bedroom.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant's Preferred Temperature
Description: Temperature is set by the individual based on their own habits and preference.
Study: NCT06772753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: active comparator for psychedelic effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: psychoactive substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM)
Description: psychoactive substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyltryptamine (DMT)
Description: psychoactive substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylenedioxymethamphetamine (MDMA)
Description: psychoactive substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC)
Description: psychoactive substance
Study: NCT06773273

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CapsuLaser-Assisted Capsulorhexis and Flanged Prolene Suture
Description: CapsuLaser-Assisted Capsulorhexis and Flanged 6-0 Prolene Suture for Cionni Ring Scleral Fixation
Study: NCT06770452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: HRS-4642 is a KRAS G12D inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab is a humanized IgG 1 monoclonal antibody targeting EGFR
Study: NCT04774965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slumber Curve sleep aid
Description: Patients who undergo rotator cuff repair and have been consented and randomized to the experimental group will be given a Slumber Curve sleep aid to be used during sleep. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Slumber Curve, patients will be given instructions on how to use the sleep aid while sleeping, and will be asked to use Slumber Curve nightly.
Study: NCT06770452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + nab-paclitaxel
Description: Albumin paclitaxel 125mg/m2 intravenous infusion, gemcitabine 1000mg / m2, D1,8, a cycle every 3 weeks
Study: NCT06772376

Intervention type: DIAGNOSTIC_TEST
Intervention: SERS sensor based on CHA reaction
Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
Study: NCT06772935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Electro-acupuncture
Description: A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.
Study: NCT05364359

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Taste-test
Description: Patients will receive a dietary counseling based on a simple taste-test

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
Study: NCT04266730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANDA-VAC
Description: The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
Study: NCT05976230

Intervention type: DRUG
Intervention: Entresto
Description: There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06486779

Intervention type: OTHER
Intervention: Ofatumumab
Description: This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
Study: NCT05722652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONFIDENCE
Description: This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONFIDENCE
Description: This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination
Study: NCT06201507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days: 2 and 16 Dose: 375 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days: 2 and 16 Dose: 375 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 will be administered on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 will be administered on days 1 and 15
Study: NCT03882307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir and daclatasvir
Description: oral tablets
Study: NCT06205056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV [Arm 1]
Description: Participants in Arm 1 will receive dose-consistent injections (5x10\^10 vp/0.5 mL) at each product administration visit (Days 1, 57, and 169)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV [Arm 2]
Description: Participants in Arm 2 will initially receive a lower dose (2.5x10\^10 vp/0.25 mL) on Day 1, which will increase to the Arm 1 dose (5x10\^10 vp/0.5 mL) when subsequently administered on Days 57 and 169.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF chTrimer+ALFQ [Arm 1]
Description: Participants in Arm 1 will receive dose-consistent injections of CH505 TF chTrimer (300 µg) mixed with ALFQ (200 µg MPLA/ 100 µg QS 21) at each product administration visit on Days 1, 57, and 169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF chTrimer+ALFQ [Arm 2]
Description: Participants in Arm 2 will receive 30 µg, 100 µg, 150 µg, and 300 µg doses of CH505 TF chTrimer mixed with ALFQ.~Day 1: CH505 (30 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 4: CH505 (100 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 8: CH505 (150 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 15: CH505 (300 µg) +ALFQ (50 µg MPLA/ 25 µg QS 21)~Day 57: CH505 (300 µg) +ALFQ (200 µg MPLA/ 100 µg QS 21)~Day 169: CH505 (300 µg) +ALFQ (200 µg MPLA/ 100 µg QS 21)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALFQ [Arm 1]
Description: Participants in Arm 1 will receive dose-consistent injections of ALFQ (200 µg MPLA/100 µg QS-21) mixed with CH505 TF chTrimer on Days 1, 57, and 169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALFQ [Arm 2]
Description: Participants in Arm 2 will receive a lower dose of ALFQ (50 µg MPLA/25 µg QS-21) mixed with CH505 TF chTrimer during the rapid, dose-escalating injections on Days 1, 4, 8, and 15~and a dose of ALFQ similar to that used in Arm 1 (200 µg MPLA/100 µg QS-21) mixed with CH505 TF chTrimer at subsequent injections on Days 57 and 169